Abstract
The rapid increase of human infections by multidrug-resistant (MDR) Gram-negative pathogens poses a serious health threat and demands the identification of new strategies, molecular targets, and agents for the treatment of Gram-negative bacterial infections. The biosynthesis of lipid A, the membrane-anchoring portion of lipopolysaccharide (LPS), is one promising target for novel antibiotic design because lipid A is essential for LPS assembly in most Gram-negative bacteria. The first three enzymes in the biosynthesis of lipid A, UDP-N-acetylglucosamine acyltransferase (LpxA), UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase (LpxC) and UDP- 3-O-(R-3-hydroxyacyl)glucosamine N-acyltransferase (LpxD), have emerged as an attractive Gram-negative antibacterial molecular target. In this article, we review recent advances in the studies on the structures and the structure-based drug designs of the three enzymes.
Keywords: Multidrug-resistant pathogens, lipid A biosynthesis, acyltransferase, deacetylase, chemotherapy.
Current Pharmaceutical Design
Title:Lipid A Biosynthesis of Multidrug-Resistant Pathogens - A Novel Drug Target
Volume: 19 Issue: 36
Author(s): Chang-Ro Lee, Jung Hun Lee, Byeong Chul Jeong and Sang Hee Lee
Affiliation:
Keywords: Multidrug-resistant pathogens, lipid A biosynthesis, acyltransferase, deacetylase, chemotherapy.
Abstract: The rapid increase of human infections by multidrug-resistant (MDR) Gram-negative pathogens poses a serious health threat and demands the identification of new strategies, molecular targets, and agents for the treatment of Gram-negative bacterial infections. The biosynthesis of lipid A, the membrane-anchoring portion of lipopolysaccharide (LPS), is one promising target for novel antibiotic design because lipid A is essential for LPS assembly in most Gram-negative bacteria. The first three enzymes in the biosynthesis of lipid A, UDP-N-acetylglucosamine acyltransferase (LpxA), UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase (LpxC) and UDP- 3-O-(R-3-hydroxyacyl)glucosamine N-acyltransferase (LpxD), have emerged as an attractive Gram-negative antibacterial molecular target. In this article, we review recent advances in the studies on the structures and the structure-based drug designs of the three enzymes.
Export Options
About this article
Cite this article as:
Lee Chang-Ro, Lee Hun Jung, Jeong Chul Byeong and Lee Hee Sang, Lipid A Biosynthesis of Multidrug-Resistant Pathogens - A Novel Drug Target, Current Pharmaceutical Design 2013; 19 (36) . https://dx.doi.org/10.2174/13816128113199990494
DOI https://dx.doi.org/10.2174/13816128113199990494 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Proteasomes with Naturally Occurring Compounds in Cancer Treatment
Current Cancer Drug Targets Editorial [Thematic Issue: Structural Characteristics of Short Peptides Solution Recombinant Therapeutic Protein Vaccines]
Protein & Peptide Letters Nordihydroguaiaretic Acid in Therapeutics: Beneficial to Toxicity Profiles and the Search for its Analogs
Current Cancer Drug Targets Affinity Purification and Mass Spectrometry: An Attractive Choice to Investigate Protein-Protein Interactions in Plant Immunity
Current Proteomics Emerging Immunosuppressive Drugs in Kidney Transplantation
Current Clinical Pharmacology Incretins and Preservation of Endothelial Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Structure and Function of Fbxo7/PARK15 in Parkinson's Disease
Current Protein & Peptide Science Neurogenic plasticity of mesenchymal stem cell, an alluring cellular replacement for traumatic brain injury
Current Stem Cell Research & Therapy An Experimental and Theoretical Approach to Understand Fever, DENF & its Cure
Infectious Disorders - Drug Targets Herb-Drug Interactions and Mechanistic and Clinical Considerations
Current Drug Metabolism Growing Collateral Arteries On Demand
Recent Patents on Cardiovascular Drug Discovery Family C 7TM Receptor Dimerization and Activation
Endocrine, Metabolic & Immune Disorders - Drug Targets Stem Cell Therapy for Neurologic Disorders: Therapeutic Potential of Adipose-Derived Stem Cells
Current Drug Targets Cancer/Testis Antigens Trigger Epithelial-Mesenchymal Transition and Genesis of Cancer Stem-Like Cells
Current Pharmaceutical Design Editorial [Hot Topic: Cyclooxygenases and Cyclooxygenase Inhibitors in Neurological and Psychiatric Diseases (Executive Editor: Luisa Minghetti) ]
Current Pharmaceutical Design The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Pulmonary Hypertension and Lung Transplant in Connective Tissue Disease-Interstitial Lung Disease
Current Respiratory Medicine Reviews A Novel Prescription for Alzheimer’s Disease: Targeting Hypercoagulable States
Current Neurovascular Research Antiviral Sensing in Teleost Fish
Current Pharmaceutical Design Activation of the Liver X Receptor Inhibits Th17 and Th1 Responses in Behcet`s Disease and Vogt-Koyanagi-Harada Disease
Current Molecular Medicine